Using the NYHA Classification as Forecasting Tool for Hospital Readmission and Mortality in Heart Failure Patients with COVID-19.

COVID-19 NYHA classification SARS-CoV-2 heart failure mortality risk rehospitalization

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
02 Mar 2022
Historique:
received: 05 02 2022
revised: 21 02 2022
accepted: 01 03 2022
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 11 3 2022
Statut: epublish

Résumé

During the COVID-19 pandemic, it was observed that patients with heart disease are more likely to be hospitalized and develop severe COVID-19. Cardiac disease takes the top position among patient comorbidities, heart failure (HF) prevalence reaching almost 5% in the general population older than 35 years in Romania. This retrospective study aimed to determine the potential use of the NYHA classification for HF in hospitalized patients with COVID-19 as prognostic tool for in-hospital mortality, length of hospitalization, and probability of rehospitalization for HF decompensation. We observed that patients with advanced HF had a history of significantly more comorbid conditions that are associated with worse disease outcomes than the rest of patients classified as NYHA I and II. However, regardless of existing diseases, NYHA III, and, especially, NYHA IV, patients were at greatest risk for mortality following SARS-CoV-2 infection. They required significantly longer durations of hospitalization, ICU admission for mechanical ventilation, and developed multiple severe complications. NYHA IV patients required a median duration of 20 days of hospitalization, and their in-hospital mortality was as high as 47.8%. Cardiac biomarkers were significantly altered in patients with SARS-CoV-2 and advanced HF. Although the study sample was small, all patients with NYHA IV who recovered from COVID-19 required a rehospitalization in the following month, and 65.2% of the patients at initial presentation died during the next six months. The most significant risk factor for mortality was the development of severe in-hospital complications (OR = 4.38), while ICU admission was the strongest predictor for rehospitalization (OR = 5.19). Our result highlights that HF patients continue to be vulnerable post SARS-CoV-2 infection. Physicians and policymakers should consider this population's high likelihood of hospital readmissions when making discharge, hospital capacity planning, and post-discharge patient monitoring choices.

Identifiants

pubmed: 35268473
pii: jcm11051382
doi: 10.3390/jcm11051382
pmc: PMC8910859
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Cardiovasc Dev Dis. 2021 Jun 30;8(7):
pubmed: 34209143
Biomedicines. 2021 Aug 04;9(8):
pubmed: 34440161
ESC Heart Fail. 2021 Oct;8(5):4119-4129
pubmed: 34390216
J Clin Med. 2021 Nov 27;10(23):
pubmed: 34884277
Am J Cardiol. 2020 Apr 15;125(8):1194-1201
pubmed: 32106929
J Clin Med. 2020 Jun 22;9(6):
pubmed: 32580344
Front Immunol. 2020 Oct 22;11:570681
pubmed: 33193350
Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):51-58
pubmed: 28950356
Front Cardiovasc Med. 2021 Apr 23;8:634291
pubmed: 33969006
J Clin Med. 2022 Jan 03;11(1):
pubmed: 35011982
J Card Fail. 2020 Jun;26(6):470-475
pubmed: 32315733
Am J Emerg Med. 2021 Aug;46:204-211
pubmed: 33071085
Front Med (Lausanne). 2021 Dec 15;8:760265
pubmed: 34977066
J Clin Med. 2021 Jun 16;10(12):
pubmed: 34208640
Int J Mol Sci. 2021 May 12;22(10):
pubmed: 34066226
Chem Biol Interact. 2022 Jan 5;351:109738
pubmed: 34740598
JAMA. 2021 Jan 19;325(3):304-306
pubmed: 33315057
Eur Heart J. 2022 Mar 14;43(11):1104-1120
pubmed: 34734634
Circ Res. 2016 Apr 15;118(8):1313-26
pubmed: 27081112
Ther Adv Respir Dis. 2021 Jan-Dec;15:1753466621995050
pubmed: 33749408
Postgrad Med J. 2021 Mar;97(1145):175-179
pubmed: 32732260
South Med J. 2021 Jan;114(1):51-56
pubmed: 33398362
Eur Heart J. 2020 May 14;41(19):1807-1809
pubmed: 32383758

Auteurs

Ioana Mihaela Citu (IM)

Department of Internal Medicine I, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Cosmin Citu (C)

Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Florin Gorun (F)

Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Radu Neamtu (R)

Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Andrei Motoc (A)

Department of Anatomy and Embryology, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Bogdan Burlea (B)

Department of Obstetrics and Gynecology, Municipal Emergency Clinical Hospital Timisoara, 1-3 Alexandru Odobescu Street, 300202 Timisoara, Romania.

Ovidiu Rosca (O)

Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.

Felix Bratosin (F)

Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.

Samer Hosin (S)

Department of Orthopedics, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Diana Manolescu (D)

Department of Radiology, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Raul Patrascu (R)

Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Oana Maria Gorun (OM)

Department of Obstetrics and Gynecology, Municipal Emergency Clinical Hospital Timisoara, 1-3 Alexandru Odobescu Street, 300202 Timisoara, Romania.

Classifications MeSH